<DOC>
	<DOCNO>NCT03010124</DOCNO>
	<brief_summary>The investigator therefore propose conduct biological study prospectively collect patient tumour sample , ascites , blood residual sample ( feces , urine , cervical smear ) throughout disease course marker ( diagnosis change treatment ) correlate outcome order investigate genetic diversity OC prior treatment adaptation follow treatment contribute chemotherapy resistance . In addition freshly collect ascitic sample ( tumour sample ) subject ex vivo DNA repair functional assay isolate primary culture ( establish xenograft ) target validation experiment .</brief_summary>
	<brief_title>Prognostic Predictive Biomarkers Ovarian Cancers</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>1 . New patient diagnosis OC , 2 . Previously treat patient primary tumour sample available present progressive disease , consent CT guide biopsy relapsed disease , 3 . Previously treat patient primary tumour sample available schedule surgery relapse disease . 4 . Signed informed consent 5 . Age â‰¥ 18 6 . Patient affiliate social security regimen beneficiary 1 . Patients fit inclusion criterion refuse antitumoral treatment ; 2 . Coagulation abnormality contraindicate biopsy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>